Publications acknowledging the platform
2024
Petersen J, et al. GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature. 2024 May;629(8014):1133-1141. doi: 10.1038/s41586-024-07419-8. Epub 2024 May 15.
Lund C, et al. Protection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4R. Nat Commun. 2024 Feb 8;15(1):1192. doi: 10.1038/s41467-024-45223-0.
Pendergrast LA, et al. Metabolic plasticity and obesity-associated changes in diurnal postexercise metabolism in mice. Metabolism. 2024 Mar 11:155834. doi: 10.1016/j.metabol.2024.155834. Epub ahead of print.
Fadahunsi N, et al. Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment. Sci Adv. 2024 Mar;10(9):eadg2636. doi: 10.1126/sciadv.adg2636. Epub 2024 Mar 1.
Falk S, et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Rep. 2023 May 30;42(5):112466. doi: 10.1016/j.celrep.2023.112466. Epub 2023 May 5.
Lund J, et al. The anorectic and thermogenic effects of pharmacological lactate in male mice are confounded by treatment osmolarity and co-administered counterions. Nat Metab. 2023 Apr;5(4):677-698. doi: 10.1038/s42255-023-00780-4. Epub 2023 Apr 13.
2023
Lund J, et al. The anorectic and thermogenic effects of pharmacological lactate in male mice are confounded by treatment osmolarity and co-administered counterions. Nat Metab. 2023 Apr;5(4):677-698. doi: 10.1038/s42255-023-00780-4. Epub 2023 Apr 13.
Basse AL, et al. NAMPT-dependent NAD+ biosynthesis controls circadian metabolism in a tissue-specific manner. Proc Natl Acad Sci U S A. 2023 Apr 4;120(14):e2220102120. doi: 10.1073/pnas.2220102120. Epub 2023 Mar 30.
Peluso AA, et al. Oral supplementation of nicotinamide riboside alters intestinal microbial composition in rats and mice, but not humans. NPJ Aging. 2023 Apr 3;9(1):7. doi: 10.1038/s41514-023-00106-4.
Falk S, et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Rep. 2023 May 30;42(5):112466. doi: 10.1016/j.celrep.2023.112466. Epub 2023 May 5.
2022
Damgaard MV, et al. Intravenous nicotinamide riboside elevates mouse skeletal muscle NAD+ without impacting respiratory capacity or insulin sensitivity. iScience. 2022 Feb 2;25(2):103863. doi: 10.1016/j.isci.2022.103863.
2021
Grevengoed TJ, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. J Clin Invest. 2021 Mar 15;131(6):e143861. doi: 10.1172/JCI143861.
Lubberding AF, et al. Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V. Sci Rep. 2021 Jun 10;11(1):12253. doi: 10.1038/s41598-021-90452-8.
Sveidahl Johansen O, et al. Lipolysis drives expression of the constitutively active receptor GPR3 to induce adipose thermogenesis. Cell. 2021 Jun 24;184(13):3502-3518.e33. doi: 10.1016/j.cell.2021.04.037. Epub 2021 May 27.
Tozzi M, et al. Dynamic interplay between AfadinS1795 phosphorylation and diet regulates glucose homeostasis in obese mice. J Physiol. 2022 Feb;600(4):885-902. doi: 10.1113/JP281657. Epub 2021 Sep 1.
Gonzalez-Franquesa A, et al. Discovery of thymosin β4 as a human exerkine and growth factor. Am J Physiol Cell Physiol. 2021 Nov 1;321(5):C770-C778. doi: 10.1152/ajpcell.00263.2021. Epub 2021 Sep 8.
Dall M, et al. Hepatocyte-specific perturbation of NAD+ biosynthetic pathways in mice induces reversible nonalcoholic steatohepatitis-like phenotypes. J Biol Chem. 2021 Dec;297(6):101388. doi: 10.1016/j.jbc.2021.101388. Epub 2021 Nov 8.